Skip to main content
Figure 2 | BMC Pharmacology and Toxicology

Figure 2

From: Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

Figure 2

Thymus- and activation-regulated chemokine-induced increases in F-actin content of CD4 + CCR4 + T-cells in whole human blood in the absence or presence of GSK2239633 at 1 μM, 3 μM or 10 μM. The data presented are the mean of independent determinations in three donors. Error bars represent standard error of the mean.

Back to article page